ORLANDO, Fla., March 31 (Reuters) - Plavix, a blood clot preventer sold by Bristol-Myers Squibb Co (BMY.N) and Sanofi-Aventis (SASY.PA), cut the risk of stroke by 28 percent in patients vulnerable because of irregular heart beats, a large clinical study found.
